Novo Nordisk plugs hemorrhage with lucrative Biopharm unit restored to growth

The Danish pharmaceutical giant's golden business area has made it through recent years with more skin left on its nose than many had feared a few years back.

Photo: Novo Nordisk / PR

The most lucrative unit of Novo Nordisk's business, Biopharm, has stopped capital from hemorrhaging and is in fact now restored to to growth.

This is not least attributable to hemophilia treatment Novoseven, sales of which have in fact managed to grow during the first six months of this year – a development that can certainly be felt being that the biofarma division accounts for roughly 15 percent of Novo Nordisk's consolidated business.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs